NCT02436577View on ClinicalTrials.gov

Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
BioequivalenceHealthy Japanese SubjectsPharmacokinetics
Interventions
DRUG

Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water

Ticagrelor 90 mg OD tablet, single dose

DRUG

Ticagrelor OD tablet (90 mg single dose) administered without water

Ticagrelor 90 mg OD tablet, single dose

DRUG

Ticagrelor IR tablet (90 mg) administered with 150 mL of water

Ticagrelor 90 mg IR tablet, single dose

Trial Locations (1)

Unknown

Research Site, Harrow

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY